Clinical trials
Phase 2 Urinary Bladder Neoplasms trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2004 | 1 |
| 2008 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 5 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Active, not recruiting | 3 |
| Recruiting | 2 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Acrotech Biopharma Inc. | 1 |
| Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 1 |
| BicycleTx Limited | 1 |
| Boehringer Ingelheim | 1 |
| Daiichi Sankyo | 1 |
| Day One Biopharmaceuticals, Inc. | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Jules Bordet Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 15 |
| Carcinoma, Transitional Cell | 5 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Melanoma | 3 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Astrocytoma | 1 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.